ExodusPoint Capital Management LP Buys New Position in Immunome, Inc. $IMNM

ExodusPoint Capital Management LP bought a new stake in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 779,578 shares of the company’s stock, valued at approximately $16,745,000. ExodusPoint Capital Management LP owned approximately 0.71% of Immunome at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Persistent Asset Partners Ltd purchased a new stake in Immunome in the fourth quarter valued at approximately $183,000. Aster Capital Management DIFC Ltd purchased a new stake in Immunome in the fourth quarter valued at approximately $121,000. Squarepoint Ops LLC purchased a new stake in Immunome in the fourth quarter valued at approximately $630,000. Sofinnova Investments Inc. grew its position in Immunome by 271.2% during the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after acquiring an additional 1,182,426 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in Immunome during the fourth quarter valued at approximately $1,565,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $17.91 on Wednesday. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The firm’s 50 day simple moving average is $21.62 and its two-hundred day simple moving average is $21.70. The stock has a market capitalization of $2.03 billion, a P/E ratio of -7.53 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, equities analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at approximately $7,560,533.09. This trade represents a 9.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jack Higgins sold 9,438 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the transaction, the insider owned 22,000 shares in the company, valued at $476,080. This represents a 30.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 139,438 shares of company stock worth $2,964,664 over the last ninety days. Company insiders own 7.21% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on IMNM shares. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Friday, June 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Finally, Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.